Pacemaker and Defibrillator Patients Adhering to Remote Monitoring with St. Jude Medical's Merlin Technology Saw More than Double Survival Rate

St.
Jude Medical, Inc. (NYSE:STJ), a global medical device company,
announced that data presented during a Late Breaking Clinical Trial
Session during Heart Rhythm 2014, the Heart Rhythm Society's Annual
Scientific Sessions, found an association between adherence to remote
monitoring with the St. Jude Medical Merlin™ Remote Monitoring System
and a reduction in patient mortality. Results from more than 260,000
patients implanted with either pacemakers or defibrillators demonstrated
that patients with high adherence to remote monitoring had more than
twice (2.4x) the probability of survival than that of patients without
remote monitoring.

The prospective, observational study of U.S. patients also found that
the greater adherence to remote monitoring, the better the patient
fared. Patients with high adherence to remote monitoring - measured as
weekly transmission of patient data from the Merlin@Home System to the Merlin.net™
Patient Care Network at least 75 percent of the time - overall had a
58 percent reduced likelihood of mortality than patients not using
remote monitoring and a 35 percent reduced likelihood of mortality than
patients with low remote monitoring. Though there was geographic
variability, socioeconomic factors were not associated with remote
monitoring use.

"This study is the first of its kind to find increased survival when
remote monitoring is utilized in pacemaker patients," said Dr. Suneet
Mittal, director of EP at the Valley Hospital Health System of NY and
NJ. "Furthermore, our data suggest that, irrespective of whether a
patient has a pacemaker or defibrillator, higher use of remote
monitoring is associated with better survival. Although these
asociations require further investigation, these important observations
should have significant implications for individual patient care and
best-practice guidelines."

All St. Jude Medical FDA-approved implantable cardiac devices capable of
radiofrequency (RF) remote monitoring were included in the study, which
had a cohort of 262,564. This is the largest study to-date of remote
monitoring pacemaker patients, and one of the largest for remote
monitoring overall.

"Patients with implanted cardiac devices are typically required to visit
doctors' offices several times per year to have their device performance
checked, which for many can be impractical. This new research
demonstrates that the Merlin Patient Care System not only adds
convenience for physicians and patients, it helps patients to live
longer," said Dr. Mark D. Carlson, chief medical officer for St. Jude
Medical.

About the Merlin Patient Care System

The Merlin Patient Care System supports St. Jude Medical cardiac
resynchronization therapy (CRT) devices, implantable cardioverter
defibrillators (ICDs) and pacemakers. The system was designed to help
physicians efficiently analyze therapeutic and diagnostic data.

Once a supported device is implanted, the Merlin.net Patient Care
Network gathers and stores data from the implant procedure, in-clinic
follow-up visits and from remote device transmissions sent from a
patient's home. Remote transmissions are sent via the Merlin@home™
Transmitter, a system that allows patient data from an implanted cardiac
device to be wirelessly downloaded and securely transmitted for
clinician review. Patients using a Merlin@home transmitter are able to
transmit data to their physician via a broadband Internet connection,
cellular network and standard phone line.

St.
Jude Medical is a global medical device manufacturer dedicated to
transforming the treatment of some of the world's most expensive
epidemic diseases. The company does this by developing cost-effective
medical technologies that save and improve lives of patients around the
world. Headquartered in St. Paul, Minn., St. Jude Medical has four major
clinical focus areas that include cardiac rhythm management, atrial
fibrillation, cardiovascular and neuromodulation. For more information,
please visit sjm.com
or follow us on Twitter (News - Alert) @SJM_Media.

Forward-Looking Statements

This news release contains forward-looking statements within the meaning
of the Private Securities Litigation Reform Act of 1995 that involve
risks and uncertainties. Such forward-looking statements include the
expectations, plans and prospects for the Company, including potential
clinical successes, anticipated regulatory approvals and future product
launches, and projected revenues, margins, earnings and market shares.
The statements made by the Company are based upon management's current
expectations and are subject to certain risks and uncertainties that
could cause actual results to differ materially from those described in
the forward-looking statements. These risks and uncertainties include
market conditions and other factors beyond the Company's control and the
risk factors and other cautionary statements described in the Company's
filings with the SEC (News - Alert), including those described in the Risk Factors and
Cautionary Statements sections of the Company's Annual Report on Form
10-K for the fiscal year ended December 28, 2013 and Quarterly Report on
Form 10-Q for the fiscal quarter ended March 29, 2014. The Company does
not intend to update these statements and undertakes no duty to any
person to provide any such update under any circumstance.